BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,640,067 | -29.7% | 552,961 | -15.7% | 0.01% | -27.3% |
| Q2 2023 | $53,518,606 | +67.8% | 655,624 | +52.5% | 0.01% | +57.1% |
| Q1 2023 | $31,886,057 | +63.8% | 429,789 | +83.0% | 0.01% | +75.0% |
| Q4 2022 | $19,462,645 | +28.5% | 234,829 | +340.3% | 0.00% | 0.0% |
| Q3 2022 | $15,148,000 | -24.7% | 53,337 | -8.0% | 0.00% | -20.0% |
| Q2 2022 | $20,105,000 | -33.0% | 58,003 | -16.3% | 0.01% | -16.7% |
| Q1 2022 | $30,020,000 | -53.8% | 69,323 | -44.8% | 0.01% | -53.8% |
| Q4 2021 | $64,940,000 | +2.6% | 125,528 | -3.9% | 0.01% | 0.0% |
| Q3 2021 | $63,272,000 | -34.1% | 130,572 | -38.7% | 0.01% | -38.1% |
| Q2 2021 | $95,965,000 | -2.2% | 213,133 | -17.0% | 0.02% | -16.0% |
| Q1 2021 | $98,107,000 | +47.8% | 256,871 | +22.8% | 0.02% | +47.1% |
| Q4 2020 | $66,398,000 | +20.0% | 209,096 | -6.4% | 0.02% | +6.2% |
| Q3 2020 | $55,338,000 | -5.2% | 223,379 | +1.1% | 0.02% | -11.1% |
| Q2 2020 | $58,357,000 | +31.1% | 220,990 | -5.9% | 0.02% | +12.5% |
| Q1 2020 | $44,528,000 | -1.7% | 234,831 | +13.8% | 0.02% | +33.3% |
| Q4 2019 | $45,281,000 | +19.4% | 206,280 | +6.5% | 0.01% | +9.1% |
| Q3 2019 | $37,914,000 | +56.7% | 193,762 | +66.9% | 0.01% | +57.1% |
| Q2 2019 | $24,200,000 | -6.2% | 116,075 | -10.7% | 0.01% | -12.5% |
| Q1 2019 | $25,795,000 | -9.9% | 129,915 | -34.3% | 0.01% | -11.1% |
| Q4 2018 | $28,625,000 | -30.5% | 197,801 | -2.0% | 0.01% | -18.2% |
| Q3 2018 | $41,203,000 | +90.4% | 201,864 | +38.0% | 0.01% | +83.3% |
| Q2 2018 | $21,639,000 | +7.7% | 146,262 | +9.9% | 0.01% | +20.0% |
| Q1 2018 | $20,096,000 | -30.6% | 133,052 | -40.5% | 0.01% | -28.6% |
| Q4 2017 | $28,948,000 | +20.8% | 223,451 | +12.7% | 0.01% | +16.7% |
| Q3 2017 | $23,958,000 | -31.8% | 198,184 | -33.7% | 0.01% | -33.3% |
| Q2 2017 | $35,107,000 | +33.2% | 298,783 | +15.2% | 0.01% | +28.6% |
| Q1 2017 | $26,352,000 | +6.4% | 259,249 | +7.6% | 0.01% | 0.0% |
| Q4 2016 | $24,768,000 | -22.8% | 240,860 | -17.8% | 0.01% | -30.0% |
| Q3 2016 | $32,102,000 | -3.0% | 293,171 | -0.1% | 0.01% | -9.1% |
| Q2 2016 | $33,093,000 | +11.3% | 293,463 | -6.7% | 0.01% | +10.0% |
| Q1 2016 | $29,725,000 | +171.7% | 314,482 | +158.7% | 0.01% | +233.3% |
| Q4 2015 | $10,940,000 | +46.2% | 121,552 | +50.1% | 0.00% | 0.0% |
| Q3 2015 | $7,485,000 | -15.5% | 80,957 | -10.0% | 0.00% | 0.0% |
| Q2 2015 | $8,857,000 | +8.1% | 89,945 | +10.1% | 0.00% | 0.0% |
| Q1 2015 | $8,195,000 | -7.3% | 81,716 | -14.6% | 0.00% | 0.0% |
| Q4 2014 | $8,838,000 | – | 95,656 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |